Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice
Key result
Intravenous disopyramide lowers oHCM gradients more effectively than beta-blockers or verapamil.
Population
Patients with hypertrophic cardiomyopathy (HCM), particularly those with left ventricular outflow obstruction.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May guide IV drug selection for obstructive HCM gradients; leaves open randomized oral therapy comparisons.
Structured PICO
P
Population
Patients with hypertrophic cardiomyopathy (HCM), particularly those with left ventricular outflow obstruction.
I
Intervention
Pharmacologic therapy including beta-blockers, disopyramide (with or without pyridostigmine), and verapamil.
This review outlines the stepwise pharmacologic management of obstructive hypertrophic cardiomyopathy, emphasizing beta-blockers as first-line therapy and disopyramide as a secondary option.
Cite This Study
Mark V. Sherrid (2016) conducted a review in Hypertrophic Cardiomyopathy. Pharmacologic therapy (beta-blockers, disopyramide, verapamil) was evaluated. In obstructive hypertrophic cardiomyopathy, the relative efficacy for lowering gradient with intravenous drug administration was disopyramide > beta-blockade > verapamil.